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Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic
effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the
endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated. Organic cation
transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) are known to be involved in metformin
uptake and excretion in cells. In this article, we discuss the novel therapeutic possibilities for early-stage endometrial
carcinoma (EC) in women with PCOS focusing on metformin, which might have a direct effect in the endometrium
through the OCTs and MATEs. We then review the molecular mechanism(s) of the action of metformin in the
endometrium and highlight possible mechanistic insights into the inhibition of cell proliferation and tumor growth
and, ultimately, the reversal of early-stage EC into normal endometria in women with PCOS.
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The clinical problem
Endometrial carcinoma (EC) is the second most frequent
gynecological malignancy in women with 49,560 cases
reported and 8,190 deaths from this disease in the US in
2013 [1]. It has also recently been reported that more
than 1,900 women die from EC each year in the UK
(http://www.cancerresearchuk.org). The number of re-
ported cases of EC makes it the leading cause of cancer-
related deaths across the globe [2-4]. Major EC-related
symptoms include dysfunctional uterine bleeding, hyper-
menorrhea, irregular menstruation, and sterility [5]. The
two main types of EC are estrogen-dependent type I and
estrogen-independent type II carcinomas [6]. Type I EC
is the most prevalent type – accounting for 75%–85%
of all ECs – and occurs primarily in postmenopausal
women [7]. However, approximately 25% of women
with EC are pre-menopausal and 5% of cases are diag-
nosed at younger than 40 years of age [2]. Despite a* Correspondence: ruijin.shao@fysiologi.gu.se
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genesis, complete knowledge of the exact causes of EC is
still lacking. Due to the limitations of current thera-
peutic tools, surgical procedures are still the most effect-
ive first-line treatments for the early stage of this disease
[8-12]. A significant drawback to surgical interventions,
however, is that they preclude any further fertility in
women with EC.
Among numerous risk factors, polycystic ovary syn-
drome (PCOS) is commonly considered to be a signifi-
cant risk factor for the development and progression of
type I EC [7-10]. PCOS is the most common androgen-
excess disorder, and it affects 4% to 18% of all women
of reproductive age (approximately 12 to 45 years old)
and is associated with metabolic disorders and infertility
[13-15]. Women with PCOS are characterized by hyper-
androgenemia, oligomenorrhea or amenorrhea, anovula-
tory infertility, hirsutism, insulin resistance, and type 2
diabetes mellitus [13,15,16], and this suggests that the
etiology of PCOS is heterogeneous. PCOS is often diag-
nosed after the onset of puberty [13,15], but the current
lack of understanding of the etiology of this disease makes
treatment of the disease problematic.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the MEDLINE, EMBASE, and Cochrane databases has
shown that there is a close association between PCOS
and EC and that the prevalence of EC is three times
higher among women with PCOS than among women
without PCOS [9,11]. In the clinic, EC is usually pre-
ceded by, or associated with, endometrial hyperplasia
[17], which is a proliferative process that results in an in-
creased ratio of epithelial cells to stromal components in
the endometrium [6]. Endometrial hyperplasia predis-
poses for the development of EC, and a case–control
study showed that women with PCOS and endometrial
hyperplasia have a four times greater risk of developing
EC than non-PCOS women [10]. PCOS is a hyperand-
rogenic state that results in increased bioavailability of
unopposed estrogens due to the increased peripheral
conversion of endogenous androgens such as testoster-
one and androstenedione into estrogen [13,15].
Progesterone and its analogs are used as frontline
therapeutics to treat women diagnosed with typical en-
dometrial hyperplasia and early EC [3,18], and it has re-
ported that treatment with megestrol progesterone or
medroxyprogesterone can improve certain cases of en-
dometrial atypical hyperplasia, a preform of EC, in some
women with PCOS [19]. However, treatment with high
doses of progesterone can result in thromboembolism,
hyperglycemia, weight gain, and edema [20]. Moreover,
although such therapy is effective in up to 70% of wo-
men with PCOS, more than 30% of these patients fail to
respond to progesterone treatment due to progesterone
resistance [21,22].
EC can be detected at an early stage and can be cured
with hysterectomy with or without adjuvant radiother-
apy, but surgical treatment has significant financial and
quality of life costs for these patients [2,6]. Therefore,
there is a need to develop additional therapies for these
patients. This is especially the case for young women
with PCOS and early-stage EC who wish to have non-
surgical and conservative treatments so as to retain their
potential fertility.
The pathogenesis of PCOS is multifactorial and is far
from being completely understood [13,15]. It has been
proposed that there are multiple causative factors, in-
cluding peripheral insulin resistance, impaired glucose
tolerance, and dyslipidemia, which also lead to a sub-
stantially increased risk for the development of type 2
diabetes mellitus [13,15]. All of these risk factors are also
tightly linked to the initiation and progression of EC
[23-25].
The anti-cancer effects of metformin
Metformin (N,N-dimethylbiguanide), an oral biguanide
insulin-sensitizing drug, is the most widely used first-
line treatment for type 2 diabetes mellitus worldwide[26,27]. The primary functions of this drug are to inhibit
hepatic gluconeogenesis and glucose release in the liver
(which causes decreased circulating glucose and insulin
levels), to improve insulin sensitivity, and to enhance
glucose uptake and utilization in peripheral tissues such
as skeletal muscle and adipocytes [28-30]. In recent years,
multiple lines of evidence have provided support for the
hypothesis that treatment with metformin results in de-
creased incidence, progression, and mortality of different
human cancers [29,31,32] including EC [33,34]. Although
a number of in vitro studies have demonstrated the anti-
proliferative, anti-invasive, and antimetastatic effects of
metformin in multiple cancer cell types [28], including
type I EC-like cancer cells [35-39], its cellular and mo-
lecular mechanisms of anti-cancer action in the endo-
metrium of women with PCOS have not yet been fully
elucidated [40].
In this review, we will first provide an overview of the
beneficial effects that treatment with metformin has on
the endometrium of women with both PCOS and associ-
ated endometrial hyperplasia and early-stage EC. We will
also address some questions that are relevant to treat-
ment with metformin. The main part of this review will
then focus on the diverse expression and regulation of
metformin carrier proteins in the endometrium as well
as the underlying molecular mechanisms behind the ef-
fects of metformin. These mechanisms will be discussed
in terms of their potential to contribute to the reversion
of early-stage EC to normal endometria in women with
PCOS.
Review
The effects of metformin in endometrial cells
The human endometrium undergoes extraordinary growth
in a cyclical manner during the childbearing years [41] and
is responsive to ovarian steroid hormones (estrogen and
progesterone) that are essential for controlling epithelial
and stromal cell proliferation, differentiation, secretion,
and apoptosis [42]. Because estrogens act as proliferative
factors in the endometrial tissue and can lead to endomet-
rial overgrowth and hyperplasia [43], it is presumed that
the primary cause of EC is the continuous exposure of the
endometrium to estrogens [9,12]. In fact, endogenous es-
trogen levels have been shown to be increased up to three
fold in women with type I EC compared to healthy wo-
men [44]. In women with PCOS, the endometrium tends
to remain in an estrogen-mediated proliferative state due
to chronic anovulation and this results in persistent pro-
gesterone deficiency [22,42]. Progesterone and its analogs
suppress the proliferation and survival of endometrial EC
cells [2], and several animal studies have demonstrated
that treatment with metformin has a similar effect as
progesterone by reducing epithelial cell height, reducing
endometrial gland density and thickness under normal
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eration under estrogen-regulatory and diabetic conditions
[47,48].
Estrogen and progesterone mediate their biological ef-
fects via the estrogen and progesterone receptors (ER
and PR, respectively) [41]. Whether ER and PR are ex-
pressed in the endometrium of women with PCOS and
EC remains unclear, but both receptors are present in
the endometrium of women with EC alone [49]. There is
no significant difference in endometrial ER and PR ex-
pression between diabetic and non-diabetic women with
EC, but treatment with metformin decreases endome-
trial ER expression in diabetic women with EC [50].
However, in vitro studies have demonstrated that met-
formin is capable of reducing PR expression in type I EC
cells [39]. Although the biological relationship between
PCOS, diabetes, and EC is not fully understood, these
results suggest that metformin might modulate endo-
metrial steroid hormone receptor expression in women
under hormone-imbalanced conditions such as PCOS
and EC.
Positive effects of metformin in women with PCOS
Accumulating evidence from clinical studies has shown
that treatment with metformin improves menstrual cy-
clicity, increases ovulation and pregnancy rates, de-
creases circulating insulin and androgen levels, and
reduces insulin resistance in most women with PCOS
[51-59], but not all [60]. These positive systemic effects
appear to be mediated by decreased circulating insulin
levels, increased tissue-specific insulin sensitivity, and
reduction of ovarian androgen biosynthesis [26,30]. Pre-
viously, several clinical studies demonstrated that met-
formin can also improve endometrial receptivity and
enhance endometrial vascularity and blood flow in some
women with PCOS [61,62].
Promising evidence for the use of metformin in PCOS
women with EC
It is well recognized that PCOS is not a single disease or
pathological process [13,15]. In the clinic, insulin re-
sistance and hyperinsulinemia appear to be the major
contributors to the pathophysiology of PCOS in women
[13,15,63] regardless of whether or not the women are
also obese [13,15,64]. It is estimated that approximately
50%–70% of all women with PCOS suffer from insulin
resistance [16]. We and others have previously reported
that a combination of metformin and oral contraceptives
is sufficient to not only change the insulin resistance
state but also to reverse atypical endometrial hyperplasia
in women with PCOS who fail to respond to oral contra-
ceptive treatment alone. These treatments have also al-
lowed these women to preserve their fertility [65,66],
and some of these treated women have successfullygiven birth to healthy babies (our unpublished data).
These results raise the question of whether metformin
also has a beneficial effect on the endometrium in women
with PCOS and EC.
A recent study from our laboratory has shown that a
combination of metformin and oral contraceptives is
capable of reverting early-stage EC into normal endo-
metria in addition to improving insulin resistance in
women with PCOS [49]. Although this is a promising re-
sult, we note that our preliminary report must be taken
with caution and that further research is certainly nee-
ded before co-treatment with metformin and oral con-
traceptives can be recommended in clinical practice.
Having said that, the promising results with metformin
raise the questions of whether metformin alone affects
endometrial function in women with PCOS, how a
positive effect of metformin combined with oral con-
traceptives could inhibit the development of atypical
endometrial hyperplasia and EC at the molecular level,
how our findings affect treatment guidelines for PCOS
women with and without insulin resistance, whether met-
formin as a general anti-cancer drug inhibits EC develop-
ment in women regardless of whether they also have
PCOS, and whether metformin can prevent EC develop-
ment in women without endometrial pathology but only
with risk factors or in women with pre-malignant endo-
metrial disease.
Promising evidence for the use of metformin in women
with EC
It is still far too early to say whether there is any future
for metformin as a means of preventing or treating EC
in women, and there are no clinical trials assessing single
metformin treatment of recurrent or metastatic EC.
However, metformin, in combination with mammalian
target of rapamycin (mTOR) inhibitors, seems to be ef-
fective in inhibiting EC progression in women with re-
current or metastatic EC [67] and it is also associated
with improved recurrence-free survival and overall sur-
vival in postmenopausal women with diabetes mellitus
and EC [34].
Possible mechanisms of metformin in the endometrium
Expression and localization of OCTs and MATEs
Metformin is highly hydrophilic and readily crosses the
plasma membrane [68]. However, there is convincing
evidence that organic cation transporters (OCTs) are ac-
tively involved in the cellular uptake of metformin and
that multidrug and toxin extrusion proteins (MATEs)
contribute to the excretion of metformin [69]. Although
OCT1–3 and MATE1 and 2 have been identified in
humans and rodents [69] – and although OCTs and
MATEs are often co-localized in vivo [70] – the actual
distributions of OCT1–3 and MATE1 and 2 have been
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man endometrium, the specialized lining of the uterus,
is composed mainly of luminal and glandular epithelial
cells along with fibroblastic cells that make up the
stroma [71]. In our laboratory, we have recently demon-
strated the expression and localization of OCT1–3 and
MATE1 and 2 in normal human endometrium tissue
and in the rat uterus (an antibody against rat MATE2 is
not commercially available so this was not tested). Im-
munohistochemical staining revealed that OCT2, OCT3,
MATE1, and MATE2 were present in membrane and
cytoplasm of both the epithelial and stromal cells of the
human endometrium (Figure 1 B1–E1). One interesting
observation from the immunohistochemical analysis was
that OCT1 was absent in epithelial cells and was only
expressed in the stromal cells in human endometrium
(Figure 1 A1). Furthermore, in the rat uterus we ob-
served that OCT1, OCT2, OCT3, and MATE1 were
strongly expressed in luminal and glandular epithelial
cells and less strongly in stromal cells (Figure 1 A2–D2).
Western blot analysis confirmed the expression of OCT1,
OCT2, OCT3, and MATE1 in the rat uterus (Figure 1 E2).
Because specific OCTs and MATEs contribute to the ef-
fects of metformin in different tissues such as liver and
kidney [66], these findings support the hypothesis that
metformin could have a direct effect on the endometrium
in women with PCOS that is dependent on OCTs. If
proven correct, this hypothesis will not only provide an
explanation for the results of our clinical study [49], but
will also provide a novel therapeutic option for women
who might develop endometrial atypical hyperplasia and
EC even in the absence of PCOS.
Data are emerging about how the expression of dif-
ferent OCTs is regulated under both physiological and
pathological conditions. For example, the in vitro ex-
pression of OCT1 and OCT2 decreases upon activation
of the phosphatidylinositol 3-kinase (PI3K)/protein kin-
ase B (AKT) signaling pathway in vitro (cell-line sys-
tems) [72,73], and the expression of OCT1 and OCT2
decreases upon induction of diabetes in streptozotocin-
inducable diabetic rats in vivo [74]. Further, Hirsch and
colleagues have reported in vitro results showing that
the dose-dependent inhibitory regulation of androgen
synthesis by metformin requires the presence of OCTs
[75]. Although there is no direct evidence for a relation-
ship between OCT expression and metformin response
in the endometrium, a recent study has shown that the
variations in metabolic responses observed in women
with PCOS treated with metformin are probably due to
genetic variations of OCT1 [76]. It is likely, therefore,
that the tissue-specific expression and regulation of
OCTs is important for the cellular uptake of metformin
and plays a role in the in vivo therapeutic efficacy of
metformin in women with PCOS.The main targets of metformin: adenosine monophosphate-
activated protein kinase (AMPK), mTOR, and glucose
transport protein 4 (GLUT4)
Metformin has been shown to regulate multiple signal-
ing pathways [38,77], and at the molecular level AMPK
is one of the targets for metformin action in several tis-
sues and cancer cells [27,28,77,78]. It has been reported
that metformin decreases local androgen synthesis in
human ovarian cells [79,80], increases GLUT4 expres-
sion in endometrial cells from PCOS women with hyper-
insulinemia [81], inhibits cell proliferation [36,37], and
induces cell cycle arrest and apoptosis [35] in type I EC
cells, all of which have been proposed to occur through
activation of AMPK signaling [35-37,39,81,82]. Although
metformin has been shown to activate AMPK, which
subsequently inhibits mTOR activity by phosphorylating
and stabilizing the tuberous sclerosis complex-2 (TCS2)
tumor suppressor [29,31], it has also been suggested that
metformin can directly inhibit mTOR signaling inde-
pendently of AMPK activation [28,77] (Figure 2).
Based on a number of preclinical and clinical studies,
the mechanisms of metformin in different cancer cells
have been proposed to be both insulin-dependent (sys-
temic/indirect effects) and insulin-independent (local/
direct effects) [29,31]. It has been reported that metfor-
min reduces circulating insulin levels and improves insu-
lin sensitivity in non-diabetic women with early-stage
breast cancer [83]. The activities of insulin and insulin-
like growth factor-1 (IGF-1) appear to play important
roles in the development of EC [84,85], and it has been
shown that elevated levels of circulating insulin [86,87]
and endometrial IGF-1 [88] increase the aggressiveness
of EC. Moreover, insulin increases the bioactivity of IGF-
1 by downregulating the synthesis of insulin-like growth
factor binding protein-1 (IGFBP-1) in the endometrium
[89]. Although insulin and IGF-1 preferentially bind to
their own receptors – insulin receptor (IR) and IGF-1
receptor (IGF-1R), respectively [90] – they can also form
hybrid receptor complexes in response to both insulin
and IGF-1 stimulation in an equivalent manner in vivo
[91]. Activation of IR and IGF-1R leads to the phosphor-
ylation of insulin receptor substrate-1, which subse-
quently phosphorylates and activates PI3K [88,90].
The PI3K/AKT/mTOR signaling pathway is down-
stream of insulin/IGF-1 signaling and modulates cell sur-
vival, proliferation, and metabolism under physiological
and pathological conditions, including PCOS and tumor
development [63,84,85]. Several studies have demons-
trated that overexpression of IR or IGF-1R induces hu-
man endometrial hyperplasia and promotes type I EC cell
growth [39,92,93] through activation of PI3K/AKT/mTOR
signaling [39,93]. Phosphatase and tensin homolog deleted
on chromosome 10 (PTEN) is a tumor suppressor protein
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Figure 1 Comparison of endogenous OCT1, OCT2, OCT3, MATE1, and MATE2 localization in human endometria and rat uterine tissues.
Human endometrial biopsies (n = 4) and rat uteri (n = 6) were fixed in formalin and embedded in paraffin. Rabbit anti-OCT1 (AV41516, 1:100
dilution for human and rat), rabbit anti-OCT2 (HPA008567, 1:100 for human, 1:200 for rat), and rabbit anti-MATE1 (HPA021987, 1:100 for human,
1:200 for rat) were obtained from Sigma-Aldrich (Saint Louis, MO, USA). Rabbit anti-OCT3 (ab183071, 1:25 for human, 1:100 for rat) and rabbit anti-
MATE2 (ab106117, 1:100 for human) were obtained from Abcam (Cambridge, UK). The localization of OCT1–3 and MATE1 and 2 was observed
with a peroxidase-antiperoxidase detection method using a single 3,3'-diaminobenzidine (DAB) as the chromogen. Non-specific binding was
blocked with Background Sniper (Biocare Medical, CA, USA). Representative micrographs show strong OCT1 immunoreactivity in stromal cells but
not in epithelial cells in human endometria (A1). In contrast, OCT1 immunoreactivity is detected in both epithelial and stromal cells in the rat
uterus, and there is greater OCT1 immunoreactivity in the epithelial cells (A2). Representative micrographs show that immunoreactivity of OCT2,
OCT3, MATE1, and MATE2 is detected in the epithelial and stromal cells in human endometria (B1–E1) and the rat uterus (B2–D2). An antibody
against rat MATE2 is not commercially available so this was not tested. Immunofluorescent images of OCT1 are shown in the upper right corner
of A1 and A2 and were used to confirm the immunohistochemical analysis. Sections that were exposed to rabbit normal serum were used as
negative controls (F1 and F2). Hematoxylin was used to identify the cell nuclei. Epi, epithelial cells; Str, stromal cells; NRS, normal rabbit serum.
Scale bar, 100 μm. Different rat uterine tissue lysates were directly immunoblotted with antibodies against OCT1, OCT2, OCT3, or MATE1 as
indicated in E2.
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ferent cancers [94]. In human EC, disease-causing, inher-
ited mutations of PTEN occur in up to 80% of type I EC
cases [95]. When PTEN is mutated, AKT becomes consti-
tutively active and this inhibits its downstream targets,
such as TCS1/2, through excess phosphorylation [6,42].
Interestingly, liver kinase B1 (LKB1), another tumor sup-
pressor, is responsible for the phosphorylation and activa-
tion of AMPK in the liver [96], and it has been reported
that single nucleotide polymorphisms in LKB1 are associ-
ated with metformin resistance in women with PCOS
[97]. Moreover, approximately 21% of all EC tumors lose
LKB1 protein expression and this is correlated with in-
creased activation of mTOR signaling [98]. Thus it is likely
that metformin can reverse or at least reduce EC cell sur-
vival and growth through activation of AMPK that inter-
acts with the PI3K/AKT/mTOR signaling pathway and/or
through direct inhibition of mTOR and its downstream
targets.
Another potentially important element in the mechan-
ism through which metformin inhibits the development
of EC is related to GLUT4 activity. It is known that
glucose metabolism is vital for both normal and cancer
cells and that insulin can stimulate glucose uptake by
GLUTs. GLUT4 – an inducible, insulin-sensitive trans-
port protein – facilitates the entry of glucose into cells
[99]. It has been shown that although endometrial cells
in women with and without PCOS express GLUT4,
there is a progressive decrease in endometrial GLUT4 ex-
pression from healthy women to normoinsulinemic PCOS
women to hyperinsulinemic PCOS women [81,100-103].
Glucose uptake depends on the level of GLUT4 ex-
pression [99], and treatment with metformin increases
GLUT4 mRNA and protein expression in endometrial
cells from women with PCOS in vivo [81,103] and in vitro
[104], possibly through the activation of AMPK and its
downstream targets such as myocyte enhancer factor
2A [81].Endometrial stromal cells are the paracrine regulators of
epithelia-derived EC
It is well known that endometrial malignancy results
from the cancerous transformation of the epithelial cells
that line the inner surface of uterus [43]. Moreover, nu-
merous studies have shown that the stromal component
is not only supportive of tumor growth but can also be a
causative factor for the initiation and development of
many human cancers [105]. Although very little is cur-
rently known about how the paracrine interactions bet-
ween stromal and epithelial cells are regulated in human
endometrium under either physiological or pathological
conditions [17], the molecular mechanisms behind how
stromal cells influence the abnormal proliferation and
cancerous transformation of epithelial cells are clear. For
example, uterine tissue recombination experiments have
shown that stromal PR is essential for the inhibition
of estrogen-induced epithelial cell proliferation in mice
[106]. Using an in vivo epithelia-PTEN knockout mouse
model, Janzen and colleagues have revealed that decreased
expression of the stromal PR isoform (PR-A) is respon-
sible for progesterone resistance in epithelia-derived EC
cells [107]. Moreover, in vitro studies in human endomet-
rial stromal cells have demonstrated that progesterone-
stimulated IGFBP-1 expression [108,109] might inhibit
estrogen-stimulated epithelial IGF-1 expression and ac-
tivity [24,108]. Although stromal IGFBP-1 expression is
undetectable or only minimally present in endometrial
hyperplasia and EC [110], endometrial stromal cells might
play a paracrine role in the regulation of epithelia-derived
EC development in women with PCOS [25,49,110].
Taken together, the results presented above lead us to
propose the following two mechanisms behind the po-
tential anti-cancer effects of metformin in the endomet-
rium from PCOS women with early-stage EC (Figure 2).
(1) Metformin activates the AMPK pathway that sup-
presses hepatic gluconeogenesis and leads to a reduction
in circulating insulin and glucose levels. This reduction
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Figure 2 A schematic diagram representing the hypothetical mechanisms of the insulin-dependent systemic (I) and insulin-
independent direct (II) effects of metformin in the endometrium. In the endometrium, binding of insulin and IGF-1 ligands to their receptors
INSR and/or IGF-1R as homodimers or heterodimers leads to the activation of downstream signaling pathways, including the PI3K/AKT/mTOR
pathway. A number of studies have demonstrated that in vitro enhancement of the PI3K/AKT/mTOR cascade in multiple cancer cells – including
type I EC cell lines – ultimately results in specific cellular outcomes including cell proliferation, cell death, cell cycle arrest, and protein translation.
Thus, activation of the PI3K/AKT/mTOR cascade might be the underlying mechanism behind the initiation and progression of EC in women with
PCOS. Because AMPK, mTOR, and GLUT4 are considered to be central factors that are targeted by metformin, and because various OCTs and
MATEs that mediate the metformin uptake and excretion are present in endometrial epithelial and stromal cells, we propose the following two
mechanisms of metformin-induced inhibition of the PI3K/AKT/mTOR cascade in PCOS women with early stage EC. (1) Metformin activates the
AMPK pathway in the liver and suppresses hepatic gluconeogenesis. This leads to reduced levels of circulating insulin and glucose, and this
lack of substrates for IR/IGF-1R binding disrupts the activation of insulin/IGF-1 signaling pathways in the endometrial cancer cells. (2) In the
endometrium, metformin either directly targets members of the AMPK, mTOR, and GLUT4 axis in endometrial cancer cells through the activity of
epithelial OCTs and MATEs, or through stromal OCTs and MATEs in a paracrine manner to inhibit epithelia-derived cancer cell proliferation and
growth. Thick horizontal red lines indicate inhibitory effects of metformin. For references, see the text.
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tion of the insulin/IGF-1 signaling pathways in epithelia-
derived EC cells. (2) In the endometrium, metformin
either directly targets members of the AMPK, mTOR,
and GLUT4 axis in epithelia-derived EC cells through
the function of epithelial OCTs and MATEs, or inhibits
cell proliferation and growth in epithelia-derived EC
cells in a paracrine manner by targeting the AMPK and
mTOR signaling through the function of stromal OCTs
and MATEs.
Conclusion and future prospects
One causative factor of EC is PCOS, which is a com-
plex and heterogeneous endocrine disorder that affects a
large number of reproductive-age women around the
world. Many PCOS women with early EC can be cured
of their cancer, but more than 30% of such patients fail
to respond to progesterone treatment due to progester-
one resistance. Because women with PCOS and early-
stage EC are often of young age, they usually wish to
retain their potential fertility. Thus it is imperative to de-
velop new and effective non-surgical and conservative
treatments for these patients [25,49]. Our data suggest
that metformin can be advocated as another long-term
medical treatment option for these patients. Because hu-
man endometrium expresses OCTs and MATEs, the po-
tential function of these metformin carrier proteins in
the endometrium in women with PCOS and EC is a tar-
get ripe for future exploration.
The core mechanisms in the pathogenesis of human
endometrial atypical hyperplasia and EC include the ac-
tivation of insulin/IGF-1 signaling through overexpres-
sion of INSR and/or IGF-1R, the activation of PI3K/
AKT/mTOR signaling, and the loss of PTEN expression.
Thus, the effectiveness of metformin in reverting early
EC to normal endometria might be due to its anti-cancer
effects on cellular metabolism and the AMPK and mTOR
axis in the endometrium in addition to its systemic
effects. Although there has been significant progress inunderstanding the possible molecular mechanisms behind
the therapeutic and preventive potential of metformin in
women with PCOS and EC [25], the regulatory mecha-
nisms of metformin and their contribution to its anti-
cancer activity remain to be further investigated before
such treatment can become common clinical practice for
treating women with PCOS and early-stage EC.
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